We divided patients into uncategorized ADS, ADEM, MOGAD, and MS/NMO/NMOSD groups, and there was no significant difference in CSF NfL between each group (Kruskal–Wallis test, χ2 = 0.451, P = 0.451). This evidence concerns the gene NEFL and myeloid sarcoma.